Bone Marrow Suppression by Human Herpesvirus-6: Comparison of the A and B Variants of the Virus

To the Editor:
The ability of human herpesvirus-6 (HHV-6) to cause disease in patients with immature immune systems and acquired immunodeficiencies is becoming increasingly recognized. A recent report in Blood' provided strong evidence for a role of HHV-6 as a cause of severe bone marrow suppression in bone marrow transplant (BMT) patients during the posttransplant period. Interestingly, BM suppression has been observed as a frequent complication of primary HHV-6 infections in infants?
The term HHV-6 actually encompasses two distinct variants of the virus, designated the A (HHVdA) and B (HHV-6B) variant^.^ These variants differ from one another with respect to their cell tropism, genomic DNA sequences, and protein expression. It is clear that the vast majority of primary HHV-6 infections in infants and reactivated infections in BMT patients are due to HHV-6B.4.' The relative pathogenic potentials of the two variants remain largely unexplored. In BMT patients, the BM suppression associated with BM infection by HHVdB appears to most commonly manifest as a long-term, moderately severe suppression of BM function that usually involves multiple lineages of BM cells ' (D. Carrigan, unpublished observations) . Chronic BM suppression associated with persistent BM infection by HHVdB in an immunologically intact individual has been described? In contrast, the only known instance of HHV-6A infection of the BM of a BMT patient was associated with the abrupt and dramatic appearance of aplastic anemia associated with an essentially empty BM at biopsy in a patient almost 2 years after his BMT?
These results suggest that the A variant of HHV-6 may possess increased pathogenetic virulence compared with the B variant of the virus. We sought to confirm or refute this hypothesis by means of a variety of in vitro assays aimed at determining the effects of the two virus variants on BM function. Use of these assays has been described previously from our l a b o r a t o~y .~~~ A methylcellulose-based human BM stem cell proliferation kit (GIBCO BRL, Gaithersburg, MD) was used to quantify colony-formation units (CFU). Stem cells evaluated by this procedure were the precursor to the granulocyte and macrophage lineages (CFU-GM), the erythroid burst-forming unit (BFU-E), and the multipotential precursor of the granulocyte, erythrocyte, monocyte, and megakaryocyte lineages (CFU-GEMM). The stromal cell outgrowth assay was performed as described? Macrophage outgrowth from bone marrow cells exposed to granulocytemacrophage colony-stimulating factor (GM-CSF) was measured as described previously?
HHV-6w, also known as the DC strain of HHV-6, was isolated in this laboratory and is considered to be a prototype of HHV-6B? Normal human peripheral blood mononuclear cells were purified from the blood of healthy donors by Ficoll-Hypaque density gradient centrifugation, stimulated with phytohemagglutinin (PHA), and used to prepare stocks of HHV-6w. HHV-6Gs, a prototype of the A variant of HHV-6; was obtained from the National Institutes of Health AIDS Research and Reference Reagent Program and was grown in the HSB-2 line of human T-cell leukemia cells. Medium freshly obtained from infected cultures showing greater than 80% involvement with viral cytopathic effects were clarified by centrifugation and used as viral stocks. Mock viral preparations, ie, supernatant medium from parallel uninfected HSB-2 cell or PHA blast cultures, were used in all experiments to control for cellular products and cytokines. Both virus-containing and mock-infected materials were used at 0.5 mL per lo6 BM cells. This viral input represented Using these techniques, a direct comparison of the innate virulence of a prototype A variant of HHV-6 (HHV-6Gs) and a prototype B variant (HHV-6KF) was performed. Results are summarized in Table  I. HHV-6B was able to suppress BM function from 43% to 86% depending on the assay used. In contrast, HHV-6A-mediated suppression ranged from 94% to 98% in the different assays, showing a significantly higher degree of virulence. This difference is even more striking when the virus inputs are compared. As stated above, in these experiments the input of HHV-6A was 0.001 tissue culture infectious doses 50% (TCIDSo) per BM cell, whereas the input of HHV-6B was I .O TCIDSo per cell.
These results show that the A variant of HHV-6 has an intrinsically increased virulence with respect to BM suppression compared with the B variant of the virus. Mechanisms involved in these differences between the variants remain unexplored, but the profound biologic effects of HHV-6A associated with very low inputs of infectious virus suggest that indirect mechanisms such as inappropriate cytokine induction may be involved. 
